Comparing Two Major Biotech ETFs: FBT and IBB Strategy Differences
A look at the structural differences between the First Trust NYSE Arca Biotechnology Index Fund and the iShares Biotechnology ETF shows distinct choices in cost and concentration for everyday investors.
🧠AI AnalysisPhoto: Motley Fool
Key points
- FBT utilizes a concentrated, equal-weighted strategy with about 30 holdings.
- IBB provides broader exposure with roughly 243 holdings and a market-cap weighting approach.
- FBT delivered a 71% total return over five years compared to 40% for IBB.
- IBB features a lower expense ratio of 0.44% versus 0.55% for FBT.
Contrasting Approaches in Healthcare Sector Funds
Navigating the healthcare sector through exchange-traded funds offers everyday market participants a way to bypass the severe single-stock risks inherent in medical research companies. Two prominent options—the First Trust NYSE Arca Biotechnology Index Fund (FBT) and the iShares Biotechnology ETF (IBB)—provide entirely different strategies for capturing growth in this space.
The First Trust product relies on a concentrated, equal-weighted model holding roughly 30 positions. Its top weightings include Genmab at 4.76%, Regeneron Pharmaceuticals at 4.00%, and ADMA Biologics at 3.99%. Conversely, the iShares fund tracks a much wider benchmark featuring 243 holdings, anchored by market-cap weighting. Its largest allocations consist of Gilead Sciences at 8.97%, Amgen at 8.31%, and Vertex Pharmaceuticals at 7.73%.
Performance Metrics and Expense Ratios
Historical returns diverge notably between the two vehicles. Over a five-year period, FBT generated a total return of 71%, translating to a compound annual growth rate of 11.3%. IBB posted a 40% total return over the same timeframe, with a 6.9% compound annual growth rate.
Management expenses also separate the choices. IBB charges a lower expense ratio of 0.44%, while FBT sets its fee at 0.55%. Regarding distributions, neither vehicle provides heavy cash flow, though IBB offers a minor dividend yield of 0.2%.
What to watch next: Monitor shifts in sector-wide valuations and expense ratio adjustments as broader macroeconomic volatility persists across healthcare equities.
Source Motley Fool — fool.com/coverage/etfs/2026/11/14/two-ways-to-play-biotech-fbt-s-re… ↗
Read next
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.
🧠AI AnalysisBitcoin Eyes Resistance Near $61,800 Following Support Bounce
Bitcoin displays bullish momentum after rebounding from a key support zone, with potential movement toward the 61,800 resistance level.
🧠AI AnalysisAnalyst Suggests Taking Profits on Global X MSCI Colombia ETF
Market analysts recommend locking in gains on Colombian equities amid current macroeconomic conditions.
🧠AI AnalysisAnthropic IPO Momentum Fades as Stock Slips Below Opening Levels
Anthropic shares declined following a strong market debut, prompting market watchers to evaluate potential short-term downside risks.
📈MarketsBitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound
Bitcoin is hovering near a vital monthly support level, with technical analysts warning that a close below this threshold could risk a drop toward the $32,000 region.